Alzheimer’s therapy for people with Down syndrome

Alzheimer; News from the web:

Researchers at the University of Colorado School of Medicine have been awarded a $4.6 million, five-year grant by the National Institute on Aging to study whether a potential Alzheimer’s disease treatment is safe and effective in improving cognitive function in young adults with Down syndrome.

Huntington Potter, PhD, professor of neurology, and Peter Pressman, MD, assistant professor of neurology, are principal investigators on the study of sargramostim, which is also know by the brand name Leukine, an FDA-approved drug with nearly 30 years of safe use in numerous patient populations.

“This is the first clinical trial in years to target cognition in people with Down syndrome,” said Potter, who is director of University of Colorado Alzheimer’s and Cognition Center. “We are breaking new ground in studying both of these disorders – Down syndrome and Alzheimer’s disease. We hope that this therapy will greatly improve their quality of life.”

Read all about it HERE